# Research Review: What the TB-500 and Thymosin Beta-4 Literature Shows

> TB-500 research covers wound healing, angiogenesis, cardiac protection, neuroprotection, and muscle repair in preclinical models. This page reviews the findings and the evidence quality, with full citations.

The TB-500 research literature is almost entirely preclinical — rodent and equine models, in vitro cell assays, and some limited doping-control analysis. As of 2026, no completed Phase I/II human clinical trial on the TB-500 fragment (Ac-LKKTETQ) specifically has been published [16]. A 2026 Sports Medicine review concluded that TB-500 and similar unapproved peptides have favorable tissue repair outcomes in animal models but that "rigorous human safety data are scarce" [20].

## What Does TB-500 Do? Proposed Mechanisms

TB-500 acts as a mimic of the central actin-binding domain (residues 17–23) of Thymosin Beta-4. By binding G-actin monomers, it regulates the free-actin pool available for directed cell migration [1].

Documented downstream effects in preclinical models include:

- **VEGF/VEGFR2 upregulation** — promotes angiogenesis in damaged tissue; Tβ4 stabilizes HIF-1alpha, maintaining VEGF expression [13]
- **Matrix metalloproteinase induction** — upregulates MMP-2 and MMP-9, enabling cell migration [1]
- **NF-κB suppression** — inhibits TNF-alpha-induced NF-κB and downstream IL-8 expression [15]
- **Akt/ILK survival signaling** — activates anti-apoptotic pathways in ischemic tissue [5, 6]
- **Macrophage M2 polarization** — shifts macrophage phenotype from M1 to M2 [22]

## TB-500 Benefits Observed in Preclinical Research

**Wound healing and dermal repair.** Tβ4 increased reepithelialization by 42–61% in rat full-thickness wound models [3]. The synthetic LKKTETQ fragment replicated this in diabetic and aged mice [2].

**Ligament and tendon repair.** Local delivery of 1 µg Tβ4 (in fibrin sealant) to surgically transected rat MCL produced superior biomechanical properties and collagen fibril architecture at four weeks [9]. Equine use was widespread enough to prompt WADA doping-control methodology [18].

**Skeletal muscle repair.** Tβ4 accelerated myoblast wound closure and recruited satellite cells to injury sites in mouse models [10]. In dystrophic mice, 6 months of 150 µg twice weekly increased regenerating fibers without functional improvement [11].

**Cardiac protection.** Tβ4 at 5.37 mg/kg IP in Sprague-Dawley rats reduced infarct size by 43% at 28 days [6]. In mouse coronary artery ligation, Tβ4 promoted cardiomyocyte survival and upregulated ILK/Akt signaling [5].

**Neuroprotection.** In rat TBI models, 30 mg/kg IP (6 hours post-injury) improved sensorimotor recovery, reduced cortical lesion volume, and enhanced hippocampal neurogenesis [7]. Optimal dose for stroke recovery was calculated at 3.75 mg/kg [8].

**Hair follicle activation.** Tβ4 promotes hair growth in rat and mouse models via follicle stem cell activation and differentiation [4].

## TB-500 vs BPC-157: How They Differ in Animal Models

BPC-157 operates via NO-synthase modulation and localized cytoprotection. TB-500 operates through systemic actin regulation, angiogenesis, and immune modulation [1, 21]. No published head-to-head study compares them directly.

## TB-500 and BPC-157: Mechanistic Differences in Recovery Research

Different mechanisms, different tissue systems, different evidence bases. TB-500 has a stronger cardiac and wound-healing dataset; BPC-157 has a stronger gut-healing dataset. No combination study exists.

## Human Clinical Trial Landscape for TB-500

As of 2026, no completed Phase I/II human clinical trial on TB-500 (Ac-LKKTETQ) has been published. NCT07487363 is registered but not confirmed as completed. The Phase I trial of full-length Tβ4 IV (no serious adverse events) and the Phase II ophthalmic trial [23] both cover the parent protein, not the fragment [16].

## References

[1] Philp D, et al. Thymosin beta4 promotes MMP expression during wound repair. J Cell Physiol. 2006;208(1):84-92.
[2] Philp D, et al. Thymosin beta 4 and LKKTETQ peptide promote dermal wound repair in diabetic and aged mice. Wound Repair Regen. 2003;11(1):19-24.
[3] Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368.
[4] Philp D, et al. Thymosin beta 4 induces hair growth via stem cell migration. Ann NY Acad Sci. 2007;1112:95-103.
[5] Srivastava D, et al. Thymosin beta4 is cardioprotective after myocardial infarction. Ann NY Acad Sci. 2007;1112:161-170.
[6] Bao W, et al. Cardioprotection by systemic dosing of thymosin beta four. Front Pharmacol. 2013;4:149.
[7] Xiong Y, et al. Neuroprotective effects of thymosin beta4 in TBI rats. J Neurosurg. 2012;116(5):1081-1092.
[8] Morris DC, et al. A dose-response study of thymosin β4 for acute stroke. J Neurol Sci. 2014;345(1-2):52-56.
[9] Xu B, et al. Thymosin β4 enhances medial collateral ligament healing in rat. Regul Pept. 2013;184:1-5.
[10] Tokura Y, et al. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. J Biochem. 2011;149(1):43-48.
[11] Spurney CF, et al. Chronic Thymosin β-4 in the dystrophin-deficient mouse. PLoS One. 2010;5(1):e8976.
[13] Jo JO, et al. Thymosin β4 induces VEGF expression via HIF-1α. Biochim Biophys Acta. 2010;1803(11):1244-1251.
[15] Qiu P, et al. Thymosin β4 inhibits TNF-α-induced NF-κB activation. PLoS One. 2011;6(5):e20357.
[16] Wang X, et al. Phase I study of recombinant human thymosin β4. J Cell Mol Med. 2021;25(17):8390-8399.
[18] Barton C, et al. Doping control analysis of TB-500 in equine samples. Drug Test Anal. 2013;5(9-10):819-827.
[20] Mendias CL, Awan TM. Safety and Efficacy of Unapproved Peptide Therapies. Sports Medicine. 2026.
[21] Philp D, Kleinman HK. Animal studies with thymosin beta. Ann NY Acad Sci. 2010;1194:81-86.
[22] Zhu Z, et al. Thymosin β4 promotes M2 macrophage polarization in NAFLD. J Inflamm Res. 2025;18:5483-5498.
[23] Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: Phase II trial. Clin Ophthalmol. 2015;9:863-869.

---

Peer-reviewed findings on TB-500, read warmly and honestly — the evidence gaps are noted alongside the findings, and no clinic sits behind this page.